HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease).

AuthorsC Voigtländer, M Lüftl, G Schuler, M Hertl (Affiliation: Department of Dermatology, University of Erlangen-Nürnberg, Erlangen, Germany.)
JournalArchives of dermatology (Arch Dermatol) Vol. 137 Issue 12 Pg. 1571-4 (Dec 2001) ISSN: 0003-987X [Print] United States
PMID11735706 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • infliximab
  • C-Reactive Protein
Topics
  • Aged
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Arm
  • Breast Neoplasms (surgery)
  • C-Reactive Protein
  • Dermatologic Agents (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Infusions, Intravenous
  • Leukocyte Count
  • Skin Diseases, Vesiculobullous (drug therapy)
  • Thorax
  • Tumor Necrosis Factor-alpha

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD